Posted in ace2 elisa, aflatoxin elisa, Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, dylight 488, Elisa Kits, Enzymes, Equipments, Exosomes, fgf21 elisa, Gels, igf1 elisa, igf2 elisa kit, il3 elisa, Isotypes, mag antibody, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, rat elisa kits, Reagents, Recombinant Proteins, research antibody, Ria Kits, RNA, Test Kits, Vector & Virus, Western Blot
Identification of low molecular weight degradation merchandise from chitin and chitosan

Identification of low molecular weight degradation merchandise from chitin and chitosan by electrospray ionization time-of-flight mass spectrometry
The helpful results offered by chitosan oligosaccharides (COS) make them of curiosity in medical analysis.
The monomers that represent COS confer distinct properties, so controlling COS composition throughout their manufacturing is important.
On this work, we degraded chitin and chitosan polymers and recognized low molecular weight merchandise resembling COS that shaped, utilizing electrospray ionization time-of-flight mass spectrometry.
Our outcomes present that hydrochloric acid, hydrogen peroxide, and nitrous acid generate distinct merchandise from chitin and chitosan.
Hydrochloric acid degrades chitin and chitosan to provide glucosamine (GlcN) monomers and oligomers. Hydrogen peroxide degrades chitosan to provide GlcN and N-acetyl-d-glucosamine (GlcNAc) monomers and oligomers, and nitrous acid degrades chitosan to provide 2,5-anhydro- d-mannose.
Our research present that COS composition is dictated by each the degradation protocol and the beginning polymer. Moreover, our outcomes allow number of degradation protocols primarily based on their capacity to degrade chitin and chitosan and facilitate the manufacturing of COS with desired compositions.
Key phrases: Chitin; Chitosan; Mass spectrometry; Polysaccharide degradation.
Phospho-Histone H3 (Thr3) Polyclonal Antibody |
|||
A-4051 | EpiGentek |
|
|
Phospho-Histone H3 (Thr11) Polyclonal Antibody |
|||
A-4052 | EpiGentek |
|
|
Rabbit Anti-Influenza A HA (H3N2, 1-531aa/HA1+HA2) (A/Brisbane/10/2007) protein IgG, aff pure |
|||
H3N23-A | Alpha Diagnostics | 100 ul | EUR 534 |
Influenza A H3 Antibody |
|||
abx021977-1mg | Abbexa | 1 mg | EUR 1053.6 |
Influenza A H3 Antibody |
|||
abx021978-1mg | Abbexa | 1 mg | EUR 1053.6 |
Influenza A antibody |
|||
10-1096 | Fitzgerald | 500 ug | EUR 249.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1097 | Fitzgerald | 1 mg | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1098 | Fitzgerald | 1 mg | EUR 726 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1099 | Fitzgerald | 1 mg | EUR 726 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1100 | Fitzgerald | 500 ug | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1101 | Fitzgerald | 1 mg | EUR 726 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1102 | Fitzgerald | 500 ug | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1103 | Fitzgerald | 500 ug | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1241 | Fitzgerald | 500 ug | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-1243 | Fitzgerald | 500 ug | EUR 418.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-7866 | Fitzgerald | 1 mg | EUR 483.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-7867 | Fitzgerald | 1 mg | EUR 483.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50A | Fitzgerald | 1 mg | EUR 603.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50B | Fitzgerald | 1 mg | EUR 470.4 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50C | Fitzgerald | 1 mg | EUR 470.4 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50D | Fitzgerald | 1 mg | EUR 334.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50E | Fitzgerald | 1 mg | EUR 334.8 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50F | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50G | Fitzgerald | 1 mg | EUR 489.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50H | Fitzgerald | 1 mg | EUR 649.2 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50I | Fitzgerald | 1 mg | EUR 489.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50K | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50L | Fitzgerald | 1 mg | EUR 360 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50M | Fitzgerald | 1 mg | EUR 360 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50N | Fitzgerald | 1 mg | EUR 360 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50O | Fitzgerald | 1 mg | EUR 360 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50P | Fitzgerald | 1 mg | EUR 360 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50Q | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50R | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50S | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50T | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Influenza A antibody |
|||
10-I50U | Fitzgerald | 1 mg | EUR 327.6 |
Description: Mouse monoclonal Influenza A antibody |
Lung Tissue Lysate (Tumor) |
|||
1703-07 | ProSci | 0.1 mg | EUR 336.3 |
Description: Lung tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Kidney Tissue Lysate (Tumor) |
|||
1707-07 | ProSci | 0.1 mg | EUR 336.3 |
Description: Kidney tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Normal) |
|||
1710-07 | ProSci | 0.1 mg | EUR 260.7 |
Description: Breast tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
|||
1714-07 | ProSci | 0.1 mg | EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Colon Tissue Lysate (Normal) |
|||
1715-07 | ProSci | 0.1 mg | EUR 260.7 |
Description: Colon tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Influenza A Hemagglutinin H1 (A/Brisbane/59/2007)(H1N1) Peptide |
|||
11-563 | ProSci | 0.05 mg | EUR 632.4 |
Description: Influenza A Hemagglutinin H1 (A/Brisbane/59/2007)(H1N1) Peptide |
Influenza A Hemagglutinin H1 (A/Brisbane/59/2007)(H1N1) Peptide |
|||
11-564 | ProSci | 0.05 mg | EUR 632.4 |
Description: Influenza A Hemagglutinin H1 (A/Brisbane/59/2007)(H1N1) Peptide |
MBD1 Polyclonal Antibody |
|||
A-1006 | EpiGentek |
|
|
5-Methylcytosine (5-mC) Monoclonal Antibody [33D3] |
|||
A-1014 | EpiGentek |
|
|
5-Hydroxymethylcytosine (5-hmC) Monoclonal Antibody [HMC/4D9] |
|||
A-1018 | EpiGentek |
|
|
PRDM4 Polyclonal Antibody |
|||
A-2004 | EpiGentek |
|
|
PRDM5 Polyclonal Antibody |
|||
A-2005 | EpiGentek |
|
|
PRDM10 Polyclonal Antibody |
|||
A-2010 | EpiGentek |
|
|
PRDM11 Polyclonal Antibody |
|||
A-2011 | EpiGentek |
|
|
PRDM13 Polyclonal Antibody |
|||
A-2013 | EpiGentek |
|
|
PRDM16 Polyclonal Antibody |
|||
A-2016 | EpiGentek |
|
|
PRDM17 Polyclonal Antibody |
|||
A-2017 | EpiGentek |
|
|
EZH1 Polyclonal Antibody |
|||
A-2018 | EpiGentek |
|
|
HSF1 Polyclonal Antibody |
|||
A-2401 | EpiGentek |
|
|
PRMT3 Polyclonal Antibody |
|||
A-3003 | EpiGentek |
|
|
SET1 Polyclonal Antibody |
|||
A-3011 | EpiGentek |
|
|
SET07 Polyclonal Antibody |
|||
A-3013 | EpiGentek |
|
|
LSD1 Polyclonal Antibody |
|||
A-3018 | EpiGentek |
|
|
HDAC10 Polyclonal Antibody |
|||
A-4010 | EpiGentek |
|
|
PCAF Polyclonal Antibody |
|||
A-4012 | EpiGentek |
|
|
Histone H3K9ac (Acetyl H3K9) Polyclonal Antibody |
|||
A-4022 | EpiGentek |
|
|
Histone H3K14ac (Acetyl H3K14) Polyclonal Antibody |
|||
A-4023 | EpiGentek |
|
|
Histone H3K18ac (Acetyl H3K18) Polyclonal Antibody |
|||
A-4024 | EpiGentek |
|
|
Histone H3K23ac (Acetyl H3K23) Polyclonal Antibody |
|||
A-4025 | EpiGentek |
|
|
Histone H3K56ac (Acetyl H3K56) Polyclonal Antibody |
|||
A-4026 | EpiGentek |
|
|
Histone H3K4me1 (H3K4 Monomethyl) Polyclonal Antibody |
|||
A-4031 | EpiGentek |
|
|
Histone H3K4me2 (H3K4 Dimethyl) Polyclonal Antibody |
|||
A-4032 | EpiGentek |
|
|
Histone H3K4me3 (H3K4 Trimethyl) Polyclonal Antibody |
|||
A-4033 | EpiGentek |
|
|
Histone H3K9me1 (H3K9 Monomethyl) Polyclonal Antibody |
|||
A-4034 | EpiGentek |
|
|
Histone H3K9me2 (H3K9 Dimethyl) Polyclonal Antibody |
|||
A-4035 | EpiGentek |
|
|
Histone H3K9me3 (H3K9 Trimethyl) Polyclonal Antibody |
|||
A-4036 | EpiGentek |
|
|
Histone H3K27me1 (H3K27 Monomethyl) Polyclonal Antibody |
|||
A-4037 | EpiGentek |
|
|
Histone H3K27me2 (H3K27 Dimethyl) Polyclonal Antibody |
|||
A-4038 | EpiGentek |
|
|
Histone H3K27me3 (H3K27 Trimethyl) Polyclonal Antibody |
|||
A-4039 | EpiGentek |
|
|
Histone H3K36me1 (H3K36 Monomethyl) Polyclonal Antibody |
|||
A-4040 | EpiGentek |
|
|
Histone H3K36me2 (H3K36 Dimethyl) Polyclonal Antibody |
|||
A-4041 | EpiGentek |
|
|
Histone H3K36me3 (H3K36 Trimethyl) Polyclonal Antibody |
|||
A-4042 | EpiGentek |
|
|
Histone H3K79me1 (H3K79 Monomethyl) Polyclonal Antibody |
|||
A-4043 | EpiGentek |
|
|
Histone H3K79me2 (H3K79 Dimethyl) Polyclonal Antibody |
|||
A-4044 | EpiGentek |
|
|
Histone H3K79me3 (H3K79 Trimethyl) Polyclonal Antibody |
|||
A-4045 | EpiGentek |
|
|
Histone H4K20me1 (H4K20 Monomethyl) Polyclonal Antibody |
|||
A-4046 | EpiGentek |
|
|
Histone H4K20me2 (H4K20 Dimethyl) Polyclonal Antibody |
|||
A-4047 | EpiGentek |
|
|
Histone H4K20me3 (H4K20 Trimethyl) Polyclonal Antibody |
|||
A-4048 | EpiGentek |
|
|
Histone H3K27ac (Acetyl H3K27) Polyclonal Antibody |
|||
A-4708 | EpiGentek |
|
|
CRISPR Cas9 Monoclonal Antibody [7A9] |
|||
A-9000 | EpiGentek |
|
|
CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4] |
|||
A-9001 | EpiGentek |
|
|
Influenza A Virus H3 Antigen Antibody |
|||
abx415738-01mg | Abbexa | 0.1 mg | EUR 861.6 |
Influenza A virus H3 PCR kit |
|||
PCR-H649-48R | Bioingentech | 50T | EUR 987.6 |
Influenza A virus H3 PCR kit |
|||
PCR-H649-96R | Bioingentech | 100T | EUR 1335.6 |
CLIMP-63 Polyclonal Antibody |
|||
A-0701 | EpiGentek |
|
|
DNMT3A Polyclonal Antibody |
|||
A-1003 | EpiGentek |
|
|
DNMT3B Polyclonal Antibody |
|||
A-1004 | EpiGentek |
|
|
Molecular docking and dynamics simulations research of OmpATb identifies 4 potential novel pure product-derived anti-Mycobacterium tuberculosis compounds
The outer membrane protein A (OmpATb) of Mycobacterium tuberculosis is a virulence issue that neutralizes the host pH to impede the uptake of hydrophilic antitubercular medicine.
Figuring out pure compounds with the potential to inhibit OmpATb might permit circumvention of the porin-like actions of OmpATb. 4 potential leads comprising ZINC000003958185, ZINC000000157405, ZINC000000001392 and ZINC000034268676 had been obtained by digital screening of 6394 various pure merchandise.
Characterization of the binding interactions of the potential leads with OmpATb revealed 9 essential residues comprising ARG86, LEU110, LEU113, LEU114, ALA115, PHE142, SER145, VAL146, and PHE151. Molecular dynamics simulations additionally revealed very secure protein-lead complexes.
Most residues contributed decrease binding energies to the general molecular mechanics Poisson-Boltzmann floor space (MM-PBSA) binding free energies of the interactions between the molecules and OmpATb protein.
Induced Match Docking (IFD) of the compounds regenerated poses of the molecular docking utilizing AutoDock Vina. These molecules might be beginning templates for designing inhibitors to bypass the pore mediating actions of OmpATb.
Based mostly on structural similarity, ZINC000034268676 was urged as a possible scaffold for designing efflux pump inhibitors of the gate mediating actions of OmpATb and should improve the uptake of hydrophilic medicine to scale back the length time of tuberculosis therapy.
Moreover, structurally comparable compounds obtainable within the DrugBank database with a similarity threshold of 0.7 have been reported to exhibit antitubercular and anti-mycobacterial actions.
These biomolecules may be additional characterised experimentally to corroborate their antitubercular exercise. Additionally, the skeletons of the molecules may be adopted as sub-structures for the design of future anti-mycobacterial medicine.
Key phrases: Antitubercular compounds; Induced-fit docking; MM-PBSA; Molecular docking; Molecular dynamics; Mycobacterium tuberculosis OmpATb; Pure merchandise; Digital screening.
Probing the Molecular-Stage Interactions in an Energetic Pharmaceutical Ingredient (API) – Polymer Dispersion and the Ensuing Affect on Drug Product Formulation.
An investigation of underlying mechanisms of API-polymer interplay patterns has the potential to offer helpful insights for choosing applicable formulations with superior bodily stability and processability.
On this examine, copovidone was used as a polymeric provider for a number of mannequin compounds together with clotrimazole, nifedipine, and posaconazole.
The various chemical constructions conferred the power for the mannequin compounds to type distinct interactions with copovidone. Rheology and nuclear magnetic resonance (NMR) had been mixed to research the molecular sample and relative power of energetic pharmaceutical ingredient (API)-polymer interactions.
As well as, the affect of the interactions on formulation processability by way of sizzling soften extrusion (HME) and bodily stability had been evaluated.The rheological response of an API-polymer system was discovered to be extremely delicate to API-polymer interplay, relying each on API chemistry and API-polymer miscibility.
Within the techniques studied, dispersed API induced a stronger plasticizer impact on the polymer matrix in comparison with crystalline/aggregated API.
Correspondingly, the processing torque by way of HME confirmed a proportional relationship with the utmost advanced viscosity of the API-polymer system. To be able to quantitatively consider the relative power of the API-polymer interplay, homogeneously dispersed API-polymer amorphous samples had been ready by HME at an elevated temperature. DSC, XRD, and rheology had been employed to verify the amorphous integrity and homogeneity of the resultant extrudates.
Subsequently, the homogeneously dispersed API-polymer amorphous dispersions had been interrogated by rheology and NMR to offer a qualitative and quantitative evaluation of the character of the API-polymer interplay, each macroscopically and microscopically.
Rheological grasp curves of frequency sweeps of the extrudates exhibited a powerful dependence on the API chemistry and revealed a rank ordering of the relative power of API-copovidone interactions, within the order of posaconazole > nifedipine > clotrimazole.
NMR knowledge offered the means to exactly map the API-polymer interplay sample and determine the particular websites of interplay from a molecular perspective. Lastly, the affect of API-polymer interactions on the bodily stability of the resultant extrudates was studied.
Qualitative and quantitative analysis of the relative power of the API-polymer interplay was efficiently achieved by using mixed rheology and NMR. Graphical Summary.
HRP-Goat Anti-Mouse Secondary Antibody |
|||
A12003 | EpiGentek |
|
|
HRP-Goat Anti-Rabbit Secondary Antibody |
|||
A12004 | EpiGentek |
|
|
Goat Anti-Rabbit Secondary Antibody, Biotin Conjugated |
|||
A12001 | EpiGentek |
|
|
Goat Anti-Rat Secondary Antibody, Biotin Conjugated |
|||
A12002 | EpiGentek |
|
|
Anti-Galectin 1 Antibody |
|||
A00470-2 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-Galectin-1 antibody |
|||
PAab03314 | Lifescience Market | 100 ug | EUR 426 |
anti- Galectin-1 antibody |
|||
FNab03314 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin-1 |
anti- Galectin-1 antibody |
|||
FNab03315 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against Galectin-1 |
Anti-Galectin-1 antibody |
|||
STJ93201 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-1. |
Anti-Galectin-1 antibody |
|||
STJ98716 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-1. |
Anti-Galectin 1 (1A8) |
|||
YF-MA13984 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to Galectin 1 |
Human Galectin-1 (LGALS1) |
|||
1-CSB-EP012882HU | Cusabio |
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
Human Galectin-1 (LGALS1) |
|||
1-CSB-EP012882HUb1 | Cusabio |
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
Human Genomic DNA |
|||
X11000 | EpiGentek |
|
|
Anti-Galectin 1/Lgals1 Antibody |
|||
A00470 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-Galectin 1 Biotinylated Antibody |
|||
A00470-Biotin | BosterBio | 50ug/vial | EUR 352.8 |
anti-Galectin 1 (1E8-1B2) |
|||
LF-MA10174 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to Galectin 1 |
Anti-Galectin 1/LGALS1 Antibody |
|||
PA1422 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-Galectin 1/LGALS1 Antibody |
|||
PB9240 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-galectin-1 (mouse) antibody |
|||
STJ72519 | St John's Laboratory | 100 µg | EUR 430.8 |
Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody |
|||
M08143-1 | BosterBio | 100ug/vial | EUR 476.4 |
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human. |
Human Brain Genomic DNA |
|||
X11001 | EpiGentek |
|
|
LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag |
|||
PROTO00214-1 | BosterBio | Regular: 10ug | EUR 380.4 |
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag |
|||
PROTP17931-1 | BosterBio | Regular: 25ug | EUR 380.4 |
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_ |
LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag |
|||
PROTP47929-1 | BosterBio | Regular: 20ug | EUR 380.4 |
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques. |
Polyclonal Goat anti-GST μ-form |
|||
GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
Human Galectin-3 (Gal-3) AssayMax ELISA Kit |
|||
EG3311-1 | AssayPro | 96 Well Plate | EUR 572.4 |
Human Galectin-4 (Gal-4) AssayMax ELISA Kit |
|||
EG3312-1 | AssayPro | 96 Well Plate | EUR 572.4 |
anti-Galectin 3 |
|||
YF-PA24079 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to Galectin 3 |
anti-galectin 9 |
|||
YF-PA24081 | Abfrontier | 50 ul | EUR 400.8 |
Description: Mouse polyclonal to galectin 9 |
anti-Galectin 3 |
|||
YF-PA12946 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to Galectin 3 |
anti-Galectin 3 |
|||
YF-PA12947 | Abfrontier | 100 ul | EUR 483.6 |
Description: Rabbit polyclonal to Galectin 3 |
anti-Galectin 3 |
|||
YF-PA12948 | Abfrontier | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal to Galectin 3 |
anti-Galectin 8 |
|||
YF-PA12951 | Abfrontier | 50 ul | EUR 435.6 |
Description: Mouse polyclonal to Galectin 8 |
anti-Galectin 13 |
|||
YF-PA18585 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to Galectin 13 |
Human Galectin-1(LGALS1) ELISA kit |
|||
1-CSB-EL012882HU | Cusabio |
|
|
Description: Quantitativesandwich ELISA kit for measuring Human Galectin-1(LGALS1) in samples from serum, plasma, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Recombinant Human Galectin-1 |
|||
7-00427 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Galectin-1 |
|||
7-00428 | CHI Scientific | 50µg | Ask for price |
Recombinant Human Galectin-1 |
|||
7-00429 | CHI Scientific | 1mg | Ask for price |
Galectin-1, human recombinant |
|||
4648-10 | Biovision | EUR 170.4 |
Galectin-1, human recombinant |
|||
4648-1000 | Biovision | EUR 1977.6 |
Galectin-1, human recombinant |
|||
4648-50 | Biovision | EUR 314.4 |
Human Galectin 1 Protein |
|||
20-abx066725 | Abbexa |
|
|
Anti-human Galectin-3 antibody |
|||
STJ15100163 | St John's Laboratory | 250 µg | EUR 403.2 |
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation |
Bovine Galectin-1 (LGALS1) |
|||
1-CSB-EP012882BO | Cusabio |
|
|
Description: Recombinant Bovine Galectin-1(LGALS1) expressed in E.coli |
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag |
|||
E80025 | EpiGentek |
|
|
Anti-Galectin-9 Antibody |
|||
A03415 | BosterBio | 100ul | EUR 476.4 |
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat. |
Anti-Galectin 2 antibody |
|||
PAab03310 | Lifescience Market | 100 ug | EUR 494.4 |
Anti-Galectin 4 antibody |
|||
PAab03311 | Lifescience Market | 100 ug | EUR 426 |
Anti-Galectin 8 antibody |
|||
PAab03312 | Lifescience Market | 100 ug | EUR 426 |
Anti-Galectin 9 antibody |
|||
PAab03313 | Lifescience Market | 100 ug | EUR 426 |
Anti-Galectin-3 antibody |
|||
PAab03316 | Lifescience Market | 100 ug | EUR 426 |
Anti-Galectin-7 antibody |
|||
PAab03318 | Lifescience Market | 100 ug | EUR 426 |
anti-Galectin-3 (6G2) |
|||
LF-MA20336 | Abfrontier | 100 ug | EUR 424.8 |
Description: Mouse monoclonal to Galectin-3 |
anti- Galectin 2 antibody |
|||
FNab03310 | FN Test | 100µg | EUR 702 |
Description: Antibody raised against Galectin 2 |
anti- Galectin 4 antibody |
|||
FNab03311 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin 4 |
anti- Galectin 8 antibody |
|||
FNab03312 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin 8 |
anti- Galectin 9 antibody |
|||
FNab03313 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin 9 |
anti- Galectin-3 antibody |
|||
FNab03316 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin-3 |
anti- Galectin-3 antibody |
|||
FNab03317 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against Galectin-3 |
anti- Galectin-7 antibody |
|||
FNab03318 | FN Test | 100µg | EUR 606.3 |
Description: Antibody raised against Galectin-7 |
Anti-Galectin-2 antibody |
|||
STJ93202 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-2. |
Anti-Galectin-4 antibody |
|||
STJ93203 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-4. |
Anti-Galectin-7 antibody |
|||
STJ93204 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-7. |
Anti-Galectin-8 antibody |
|||
STJ93205 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-8. |
Anti-Galectin-9 antibody |
|||
STJ93206 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to Galectin-9. |
Anti-Galectin-3 antibody |
|||
STJ96945 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins. |
Anti-Galectin-3 antibody |
|||
STJ97549 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (6B8). |
Anti-Galectin-3 antibody |
|||
STJ97550 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (8D7). |
Anti-Galectin-3 antibody |
|||
STJ97551 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (5D9). |
Anti-Galectin-3 antibody |
|||
STJ97601 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (2F9). |
Anti-Galectin-3 antibody |
|||
STJ97604 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (16E6). |
Anti-Galectin-3 antibody |
|||
STJ97605 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3 (1H4). |
Anti-Galectin-3 antibody |
|||
STJ97715 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Mouse monoclonal to Galectin-3. |
Anti-Galectin-3 antibody |
|||
STJ16100369 | St John's Laboratory | 1 mL | EUR 1256.4 |
Anti-Galectin-3 antibody |
|||
STJ16100782 | St John's Laboratory | 100 µg | EUR 864 |
Anti-Galectin-3 antibody |
|||
STJ180106 | St John's Laboratory | 0.1 ml | EUR 254.4 |
Anti-Galectin 3 antibody |
|||
STJ190057 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24) |
Anti-Galectin 3 antibody |
|||
STJ73098 | St John's Laboratory | 100 µg | EUR 430.8 |
Anti-Galectin 8 (3E5) |
|||
YF-MA13986 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to Galectin 8 |
Galectin 1 antibody |
|||
70R-11939 | Fitzgerald | 100 ug | EUR 483.6 |
Description: Rabbit polyclonal Galectin 1 antibody |
Galectin 1 antibody |
|||
70R-49997 | Fitzgerald | 100 ul | EUR 292.8 |
Description: Purified Polyclonal Galectin 1 antibody |
Galectin 1 antibody |
|||
70R-13963 | Fitzgerald | 100 ug | EUR 386.4 |
Description: Affinity purified Rabbit polyclonal Galectin 1 antibody |
Galectin 1 protein |
|||
30R-1385 | Fitzgerald | 100 ug | EUR 268.8 |
Description: Purified recombinant Human Galectin 1 protein |
Galectin 1 protein |
|||
30R-2371 | Fitzgerald | 50 ug | EUR 423.6 |
Description: Purified recombinant Human Galectin 1 protein |
Galectin 1 Antibody |
|||
49673-100ul | SAB | 100ul | EUR 399.6 |
Galectin 1 Antibody |
|||
49673-50ul | SAB | 50ul | EUR 286.8 |
Galectin-1 Antibody |
|||
3596-100 | Biovision | EUR 379.2 |